|
Market Closed -
Nasdaq
16:00:00 2026-02-06 EST
|
5-day change
|
1st Jan Change
|
|
485.36 USD
|
+1.34%
|
 |
+3.38%
|
-0.39%
|
|
01-26 |
United Therapeutics Corporation Announces Positive Results from Phase 1 Study of MiroliverELAP® in Patients with Acute Liver Failure
|
CI
| |
01-26 |
United Therapeutics Says Its Experimental Liver Assist Device Met Primary Goal in Phase 1 Study
|
MT
| |
01-26 |
United Therapeutics announces positive results from phase 1 study of Miroliverelap in patients with acute liver failure
|
RE
| |
01-26 |
United Therapeutics Announces Positive Results from Phase 1 Study of miroliverELAP® in Patients with Acute Liver Failure
|
BU
| |
01-22 |
United Therapeutics Corporation Announces Appointment of Kevin J. Tracey to Board of Directors, Effective January 21, 2026
|
CI
| |
01-22 |
United Therapeutics Corporation Announces Appointment of Kevin J. Tracey to its Board of Directors
|
BU
| |
01-15 |
United Therapeutics Insider Sold Shares Worth $3,900,122, According to a Recent SEC Filing
|
MT
| |
01-12 |
United Therapeutics Corporation Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 01:30 PM
| | |
01-07 |
SAB Biotherapeutics, Inc. Announces Board Changes ,Effective January 7, 2026
|
CI
| |
01-06 |
UBS Adjusts Price Target on United Therapeutics to $645 From $600, Maintains Buy Rating
|
MT
| |
01-05 |
United Therapeutics Insider Sold Shares Worth $500,015, According to a Recent SEC Filing
|
MT
| |
01-05 |
United Therapeutics Corporation to Present at the 44th Annual J.P. Morgan Healthcare Conference
|
BU
| |
12-29 |
United Therapeutics Insider Sold Shares Worth $11,572,963, According to a Recent SEC Filing
|
MT
| |
12-29 |
United Therapeutics Insider Sold Shares Worth $5,644,954, According to a Recent SEC Filing
|
MT
| |
12-23 |
United Therapeutics Insider Sold Shares Worth $3,047,201, According to a Recent SEC Filing
|
MT
| |
12-16 |
United Therapeutics Insider Sold Shares Worth $3,952,689, According to a Recent SEC Filing
|
MT
| |
12-16 |
United Therapeutics Insider Sold Shares Worth $1,742,193, According to a Recent SEC Filing
|
MT
| |
12-16 |
United Therapeutics Insider Sold Shares Worth $11,166,722, According to a Recent SEC Filing
|
MT
| |
12-10 |
United Therapeutics Insider Sold Shares Worth $3,833,374, According to a Recent SEC Filing
|
MT
| |
12-09 |
United Therapeutics Insider Sold Shares Worth $10,050,597, According to a Recent SEC Filing
|
MT
| |
12-08 |
United Therapeutics Insider Sold Shares Worth $3,870,056, According to a Recent SEC Filing
|
MT
| |
12-05 |
United Therapeutics Insider Sold Shares Worth $3,821,130, According to a Recent SEC Filing
|
MT
| |
12-02 |
United Therapeutics Insider Sold Shares Worth $10,798,079, According to a Recent SEC Filing
|
MT
| |
12-02 |
United Therapeutics Insider Sold Shares Worth $3,852,846, According to a Recent SEC Filing
|
MT
| |
12-02 |
United Therapeutics Insider Sold Shares Worth $10,079,696, According to a Recent SEC Filing
|
MT
|
No results for this search Select your edition All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
| 
